ArticlePloS one2025
The impact of baseline laboratory tests on the management of new-onset hypertension in primary care: A pilot study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Need for Community-Based Multimodal Screening for Chronic Disease and Cancer in Rural Kansas.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a key contributor to the global cardiovascular disease burden. In 2021, the World Health Organization (WHO) hypertension management guideline suggested baseline laboratory tests for patients with newly diagnosed hypertension but noted limited evidence in primary care contexts. This study evaluates the impact of baseline laboratory assessments on blood pressure control and comorbidities in newly diagnosed hypertensive patients.
methodsThis is a multicenter retrospective study that included all patients with new-onset hypertension between January 2015 and January 2020, followed in three primary health care centers until 2022. Data collection included 8 items of paraclinical tests performed at the diagnosis of hypertension: serum sodium, potassium and creatinine, lipid panel, electrocardiogram, glucose, HbA1c and urine dipstick. Complete workup was defined as having the 8 items checked and partial workup included 1-7 items. Blood pressure was assessed at one year and the final visit, which was beyond one year, in the two workup groups.
resultsOf 621 hypertensive patients, 107 with incident hypertension were analyzed (mean age: 54.8 ± 12.7 years; 58.9% women). A complete workup was done for 48 patients, partial for 52 and none for 7. Abnormalities detected included: 8.4% of patients with fasting blood glucose > 125 mg/dL, 7.5% with HbA1c > 6.5%, 1.9% with serum potassium < 3.5 mmoL/L, 54.2% with LDL Cholesterol > 100 mg/dL, 35.5% with serum creatinine > 0.8 mg/dL, and 7.5% with an estimated GFR < 60 mL/min/1.73 m2. Significant systolic blood pressure improvement was seen at 12 months in the complete workup group (129.9 ± 13.6 mmHg) vs. partial workup group (142.8 ± 18.9 mm Hg) (P = 0.003). Men and smokers were tested more often than women and non-smokers.
conclusionBaseline laboratory tests in patients with newly diagnosed hypertension help unmask comorbidities such as chronic kidney disease, diabetes, and dyslipidemia. Our findings support the use of baseline laboratory testing in order to optimize blood pressure control and individual patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.